Montville, NJ --News Direct-- PathPresenter

Pilot installation at The Ohio State University integrates ClinPx into Epic’s Beaker Laboratory Information System (LIS), allowing The Ohio State University (OSU) pathologists to receive, view, and sign out cases – uploaded from around the world – directly in Beaker.

PathPresenter, the premier digital pathology platform for education and conferences with more than 40,000 users and 20+ institutional licenses, now presents to clinical users a best-in-class clinical enterprise platform, ClinPx.

ClinPx is a custom, institution-branded, clinical enterprise platform that enables pathology consultations to be directly viewed and reported in your institution’s LIS through our proprietary backend HL7 messaging engine.

It has inbuilt quality control (QC) ensuring whole slide images are of diagnostic quality and has the ability to integrate validated AI models into the scanner-agonistic viewer.

ClinPx allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists as well as bidirectional communication channels for ordering stains and recuts. It also enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. This functionality brings the control and organization of the clinical workflow back to the end user.

Our first pilot installation with The Ohio State University Wexner Medical Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) integrates ClinPx into Epic’s Beaker LIS, allowing pathologists at The Ohio State University to receive, view, and sign out cases uploaded from around the world directly in Beaker.

“Our goal is to use ClinPix to augment OSU’s pathology clinical consultation capabilities globally. ClinPx has the ability to integrate with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate,” said Dr. Anil Parwani, vice chair of anatomic pathology at The Ohio State University College of Medicine.

Rajendra Singh, co-founder of PathPresenter, added “ClinPX creates a solution to allow for the integration of digital pathology into existing workflows used by pathologists without disruption.”

This platform is installed as a pilot project at The Ohio State University for potential expansion of its digital pathology consultation service. Dr. Parwani has no personal conflicts of interest to disclose.

PathPresenter is the world’s most widely used digital pathology platform, with a community of more than 40,000 users in 172 countries and 20+ institutional licenses. Our educational and conference module provides a seamless environment for pathologists, radiologists, clinicians, and life science researchers to use, share and collaborate with fellow clinicians throughout the world to learn, teach, present, perform research, and practice better medicine, while connecting industry to a global community of clinicians and researchers. Get started with PathPresenter, for free, at https://pathpresenter.net/.

Our new ClinPXTM clinical enterprise platform helps hospitals and labs expand the reach of their clinical consultation (2nd opinion) services globally, increase their efficiency, and optimize the user experience for both consulting pathologists and client pathologists. Through deep integration with the institution’s existing laboratory information system (LIS), consulting pathologists can receive, view, and sign out cases uploaded from around the world directly in the LIS. ClinPX allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists in addition to bidirectional communication channels for ordering stains and recuts. Further, it enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. Through a robust API, ClinPX integrates with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate.

Cory Batenchuk - SVP of Operations

View source version on newsdirect.com: https://newsdirect.com/news/pathpresenter-introduces-clinpx-a-clinical-enterprise-platform-920747661

These Fool.com contributors see happy news in the future for Novavax, Axsome Therapeutics, and Novocure.

Can federal agencies that fund early research tap a 42-year-old law to exercise "march-in" rights to get a drug made for a lower price? And could that stifle innovation?

A raft of multicancer blood tests are under development that promise early detection. Our verdict on Grail’s Galleri: An exciting innovation that’s far from routine use.

The Covid-19 health crisis isn’t over for South Florida biotech firms that continue to hone their technologies in hopes of saving lives.

Novavax signaled a positive outlook for its vaccine pipeline Wednesday with announcements at the World Vaccine Congress and an update on its COVID-19 vaccine.

These are the healthcare stocks with the best value, fastest growth, and most momentum for May 2022.

COVID cases are on the rise in the U.S., and while this uptick is so far a far cry from previous surges, it just goes to show that we're not out of the woods just yet. Since April 13, cases have increased by almost 20 percent from the previous week's average, according to the Centers for Disease Control and Protection (CDC). The CDC attributes a majority of these cases to the BA.2 variant—a sublineage of Omicron, the introduction of which caused an unpleasant surge during the holiday season. Con

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends granting marketing authorization for Incyte Corporation's (NASDAQ: INCY) capmatinib (Tabrecta) for advanced non-small-cell lung cancer (NSCLC). The positive opinion covers capmatinib as a monotherapy for advanced NSCLC harboring alterations to mesenchymalepithelial-transition factor gene (MET) exon 14 (METex14) skipping those who require systemic therapy before treatment with immunotherapy and/

President Joe Biden is sending his administration’s first national drug control strategy to Congress as the U.S. overdose death toll hit a new record of nearly 107,000 during the past 12 months. The strategy, released Thursday, is the first national plan to prioritize what's known as harm reduction, said White House drug czar Dr. Rahul Gupta. The strategy calls for changes in state laws and policies to support the expansion of harm reduction.

We want to feel confident that products have been vigorously tested when we purchase them from the store, especially when we're going to use them in the bath or shower. We rely on different soaps and shampoos to help keep our hair and bodies clean, whether we're showering to start our morning, following a workout, or to unwind after a long day of work—and we expect those products to be safe enough to use at our most vulnerable times. Unfortunately, sometimes things fall through the cracks and en

Preliminary results from an early clinical study show the combined shot could be safe and effective.

The lone doctor in a solo practice is increasingly becoming a rare sight as more physicians join large medical groups to help them navigate the challenges of the evolving health care landscape. The latest Physician Practice Benchmark survey by the American Medical Association in 2020 found 49.1% of doctors worked in a private, physician-owned practice, down 11 percentage points since 2012. Only 14% of doctors were in solo practice, down from 18.4% in 2012.

It might be time to think beyond pasta and rice for your carbs and start rooting for this vegetable.

Your primary care doctor has to confirm that you qualify. But the process through the health department may require some extra steps.

Quanterix Corp (NASDAQ: QTRX) received FDA breakthrough device designation for multiple sclerosis (MS) diagnostic. Quanterix designed its Simoa neurofilament light chain (NfL) plasma test as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS (RRMS). According to a news release, the company designed the digital immunoassay to quantitatively measure NfL in human serum and plasma. It has shown promise in conjunction with clinical, imaging, a

It's a controversial trend, to say the least.View Entire Post ›

Fauci, who has consulted multiple presidents about pandemics, weighs in on the end of mask mandates and the future of the pandemic.

The World Health Organization (WHO) on Thursday endorsed the use of Pfizer's oral COVID-19 antiviral treatment in high-risk patients after an analysis of trial data by the U.N. agency showed the therapy dramatically cut the risk of hospitalisation. Of existing COVID-19 treatments, Pfizer's Paxlovid is by far the most potent, the WHO said.

Cases were found in children aged between one and six in Alabama

WASHINGTON — Does the Biden administration really want and intend to fight for a higher court reversal of the ruling this week striking down its mask mandate on airplanes, trains and other public transportation — as its high-profile appeal of the case seemed to suggest? Legal specialists raised another possibility Thursday: The administration may instead be buying time and thinking about trying to erase the ruling — a move that would allow it to protect the powers of the Centers for Disease Cont